Amundi Asset Management US’s Blueprint Medicines BPMC Stock Holding History

Amundi Asset Management US’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$314K	Sell	3,231 -1,069	-25%	-$107K	﹤0.01%	1406
2020 Q4	$482K	Hold	4,300	–	–	﹤0.01%	1302
2020 Q3	$399K	Hold	4,300	–	–	﹤0.01%	1286
2020 Q2	$335K	Hold	4,300	–	–	﹤0.01%	1307
2020 Q1	$251K	Buy	4,300 +1,000	+30%	+$64.4K	﹤0.01%	1296
2019 Q4	$264K	Hold	3,300	–	–	﹤0.01%	1418
2019 Q3	$242K	Buy	3,300 +700	+27%	+$60.5K	﹤0.01%	1416
2019 Q2	$245K	Hold	2,600	–	–	﹤0.01%	1448
2019 Q1	$208K	Hold	2,600	–	–	﹤0.01%	1430
2018 Q4	$140	Buy	+2,600	New	+$158K	﹤0.01%	1451

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Amundi Asset Management US's BPMC Position: Q1 2021 in Review

Amundi Asset Management US reduced its Blueprint Medicines (BPMC) stake by 25% in Q1 2021, selling an estimated $107K and leaving 3,231 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #1406.

Amundi Asset Management US first reported a position in BPMC in Q4 2018 and has held it in 10 quarters since. The position peaked at $482K in Q4 2020. 264 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

Amundi Asset Management US held 3,231 shares of Blueprint Medicines worth $314K as of Q1 2021.
Amundi Asset Management US sold 1,069 Blueprint Medicines shares in Q1 2021, an estimated $107K.
Blueprint Medicines made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1406 holding.
Amundi Asset Management US first reported a position in Blueprint Medicines in Q4 2018 and has held it in 10 quarters since.
Amundi Asset Management US's Blueprint Medicines position peaked at $482K in Q4 2020.
264 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.